Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Selamectin against Rhipicephalus sanguineus and Dermacentor variabilis
Every spring dog owners ask for tick prevention because they want to protect their pet from the various tick-borne diseases. Which product do you recommend, and which product can be recommended? This article looks at the efficacy of selamectin against certain tick infestations in a number of studies.

Seven controlled studies were conducted to investigate the efficacy of selamectin against weekly infestations of dogs with Rhipicephalus sanguineus and Dermacentor variabilis.

Treatments (selamectin or vehicle alone) were applied topically at weekly, 2-week, or monthly intervals or in a `Monthly Plus` regimen (monthly treatment with an additional treatment at 14 days after the first treatment).

Selamectin was supplied in unit dose tubes designed to deliver a minimum dosage of 6mgkg(-1). The studies ranged in duration from 37 to 90 days.

Fifty adult ticks (+/-2) were applied approximately weekly, and tick counts were performed 3, 4, and 5 days after each infestation.

The efficacy of selamectin was expressed as the percentage reduction in geometric mean tick counts on selamectin-treated dogs compared with those for dogs treated with the vehicle alone (negative-control).

In one study, the engorgement of Dermacentor variabilis was assessed by weighing ticks after removal on the fifth day after each infestation. Weekly and 2-week interval treatments with selamectin provided efficacies against R. sanguineus of >89% across the entire study periods, with 100% efficacy being achieved from 21 days after the first dose and thereafter (study duration, 37 days for the weekly regimen and 44 days for the 2-week interval regimen). D. variabilis also was well controlled by the 2-week interval treatment regimen, with >96% efficacy being achieved from 21 days after the first treatment and thereafter until the end of the study (study duration: 90 days).

In five of six studies incorporating three treatments at monthly intervals, the percentage reduction in R. sanguineus and D. variabilis counts 5 days after infestation ranged from 90 to 100% in the second and third months after treatment began.

In the sixth study, reductions of > or =95% in D. variabilis counts 5 days after infestation were achieved for 2 weeks after each treatment in the second and third months. For the Monthly Plus regimen, from the second treatment (day 14) onwards, selamectin achieved 83-100% reductions in R. sanguineus and D. variabilis counts 3 days after infestation, and 94-100% reductions 5 days after infestation in three of the four studies.

In the fourth study, selamectin demonstrated good efficacy against D. variabilis for 2 weeks after each treatment.

In all seven studies, the counts from the selamectin-treated dogs were significantly (P< or =0.018) lower than those from the vehicle-treated dogs on 77 of the 80 assessments made 5 days after infestation.

Selamectin also significantly (P< or =0.0105) reduced engorgement of female D. variabilis. These studies demonstrated that selamectin, administered topically to the skin in a single spot at a minimum dosage of 6mgkg(-1) at monthly intervals, was effective in the control of experimentally induced R. sanguineus and D. variabilis infestations on dogs.


Source: Jernigan AD, McTier TL, Chieffo C, Thomas CA, Krautmann MJ, Hair JA, Young DR, Wang C, Rowan TG.(2000): Efficacy of selamectin against experimentally induced tick (Rhipicephalus sanguineus and Dermacentor variabilis) infestations on dogs. In: Vet Parasitol. 2000 Aug 23;91(3-4):359-75.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Proteasome inhibitors for canine and human osteosarcomamembers
Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. The authors compared the in vitro sensitivity of canine osteosarcoma cells derived from 4 tumours to the currently used chemotherapy drugs doxorubicin and carboplatin, and 4 new anti‐cancer drugs.

  • Pharmacokinetics of a novel mirtazapine transdermal ointment in catsmembers
  • Bacterial contamination in 50% dextrose vials after multiple puncturesmembers
  • Sotalol and the ventricular systolic function in dogs with ventricular arrhythmiasmembers
  • Life-threatening arterial haemorrhage during nephrectomymembers
  • Update to the chinchilla retinamembers
  • Vocal fold granulomas in brachycephalic dogsmembers
  • Extracellular vesicles in mammary cancer of dogs and catsmembers
  • Immunocytochemical assay using aqueous humor to diagnose feline infectious peritonitis members
  • Microbiota of traumatic, open fracture wounds and the mechanism of injury members
  • False-positive CT and radiography results for bronchial collapse in healthy dogsmembers
  • Variability of SDMA in apparently healthy dogsmembers
  • Bioavailability of suppository acetaminophen in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved